

I. AMENDMENTS

In the specification:

Please amend the paragraph starting at page 29, line 26, as follows:

E1
As described above, cell lines for 2B1 (CRL 10197), 1A7 (HB 10501), and 520C9 (HB 8696) have been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209. The ATCC accession numbers for the both antibodies disclosed herein are 452F2 (HB 10811), 741F8 (HB 10807), 520C9 (HB 8696), 759E3 (HB 10808), 454C11 (HB 8484), 387H9 (HB 10802), 113F1 (HB 8490), 317G5 (HB 8485, HB 8691), 34F2 (HB 11052), 650E2 (HB10812), 266B2 (HB 8486), 106A10 (HB 10789), 260F9 (HB 8488 and HB 8662), 33F8 (HB 8697), 9C6 (HB 10785), 35E10 (HB 10796), 140A7 (HB 10798), 788G6 (HB 8692), 200F9 (HB 10791), 697B3 (HB 10806), 120H7 (HB 10790), 203E2 (HB10799), 254H9 (HB 10792), 245E7 (HB 8489), 2G3 (HB 8491), 369F10 (HB 8682), 15D3 (HB 11342), 421E8 (HB 10793), 310B7 (HB 11752), 32A1 (HB 10795), 219F3 (HB10801), 42E7 (HB11751), 388D4 (HB 10794), 42H8 (HB 11830), 35E6 (HB 11769) and 36H3 (HB 11768).

In the claims:

E2
Please amend the claims as follows: >

Ab F2
1. (Amended) A method of inducing an immune response in a patient, comprising the step of administering a bispecific antibody to the patient, said bispecific antibody comprising a first binding site capable of recognizing and binding a first antigen wherein said first antigen is FcγRIII and further comprising a second binding site capable of recognizing and binding a second antigen, in an amount sufficient to induce production of antibodies to said second antigen in said patient, wherein said second antigen is a